MNPR Monopar TherapeuticscompanySEC Filings & Insider Trading Activity 2026
Latest Monopar Therapeutics (MNPR) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 27, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on April 20, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Monopar Therapeutics (MNPR) (SEC CIK 1645469), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Susan Rodriguez appointed Chief Commercial and Strategy Officer at Monopar Therapeutics, effective March 2, 2026
- • New C-suite role signals commercial buildout phase — typically precedes or accompanies product launch preparations
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Monopar Therapeutics (MNPR) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 20, 2026 | — | — | — |
10-K | Mar 27, 2026 | Dec 31, 2025 | — | |
8-K | Mar 27, 2026 | — | — | — |
8-K | Mar 2, 2026 | — | Analysis | — |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 12, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 31, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 12, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — | |
10-K | Mar 25, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 12, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest MNPR SEC filings in 2026?
Monopar Therapeutics (MNPR) has filed a 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on April 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did MNPR file its most recent 10-K annual report?
Monopar Therapeutics (MNPR) filed its most recent 10-K annual report on March 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view MNPR 10-Q quarterly reports?
Monopar Therapeutics (MNPR)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every MNPR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has MNPR filed recently?
Monopar Therapeutics (MNPR)'s most recent 8-K was filed on April 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find MNPR insider trading activity (Form 4)?
SignalX aggregates every MNPR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does MNPR file with the SEC?
Monopar Therapeutics (MNPR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MNPR filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Monopar Therapeutics (MNPR).
What is MNPR's SEC CIK number?
Monopar Therapeutics (MNPR)'s SEC CIK (Central Index Key) number is 1645469. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1645469 to look up all MNPR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find MNPR return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Monopar Therapeutics (MNPR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Monopar Therapeutics SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 36+ filings.